* Coherus BioSciences Inc is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2024
* The Redwood City California-based company is expected to report a 20.6% decrease in revenue to $59.23 million from $74.57 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Coherus BioSciences Inc is for a loss of 12 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Coherus BioSciences Inc is $8.00, above its last closing price of $0.75.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.29 -0.29 -0.14 Beat 51.7
Mar. 31 2024 -0.25 -0.24 -0.32 Missed -32.3
Dec. 31 2023 -0.14 -0.12 -0.62 Missed -420.3
Sep. 30 2023 -0.29 -0.27 -0.27 Met 1.7
Jun. -0.48 -0.48 -0.38 Beat 21.6
30 2023
Mar. 31 2023 -0.54 -0.57 -0.75 Missed -31
Dec. 31 2022 -0.87 -0.84 -0.60 Beat 28.4
Sep. 30 2022 -0.56 -0.57 -0.96 Missed -68.4
This summary was machine generated November 1 at 14:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments